FindTrial
Sign In

A randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of 250 mg lebrikizumab in patients with localized scleroderma (LEMO)

Status
Not yet recruiting
Phases
Phase 2
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2025-524435-39-00
Enrollment
78
Registered
2026-05-08
Start date
Unknown
Completion date
Unknown
Last updated
2026-05-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Localized Scleroderma

Brief summary

mLoSSI score after 24 weeks. Absolute change from baseline visit in mLoSSI score will be compared between groups

Interventions

DRUGEbglyss 250 mg solution for injection in pre-filled syringe
DRUGMatching placebo to IMP

Sponsors

Charite Universitaetsmedizin Berlin KöR
Lead SponsorOTHER

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Design outcomes

Primary

MeasureTime frame
mLoSSI score after 24 weeks. Absolute change from baseline visit in mLoSSI score will be compared between groups—

Outcome results

None listed

Source: EU CTIS · Data processed: May 9, 2026